Search »
- Use quotation marks (e.g., "RSR Manual") to search for exact phrases.
- You must be logged in to search for people in the Ryan White/TargetHIV community.
Content type
Topic Areas
Source
Publication Date
-
A single dose of a novel oral antibiotic called zoliflodacin has been found to be as safe and effective as standard therapy for uncomplicated urogenital gonorrhea in an international Phase 3 non-inferiority clinical trial.News Article updated on 11/16/2023
-
Integration of Buprenorphine into HIV Primary Care Settings: Curriculum
The purpose of this curriculum is to provide physicians with the information they need to educate their clinic staff and other stakeholders about integrating medication-assisted treatment (MAT) with buprenorphine into HIV primary care.
It provides a detailed overview of buprenorphine within clinical settings, from the legal requirements for implementation to step-by-step procedures for prescribing and administering buprenorphine.
Resource updated 03/12/2024
-
Integration of Buprenorphine into HIV Primary Care Settings: Training Manual
Overview of training manual on integrating buprenorphine treatment into HIV primary care.
Curriculum updated on 08/01/2012 -
Integration of Buprenorphine into HIV Primary Care Settings: Curriculum
Curriculum updated on 08/01/2012 -
Buprenorphine FAQ and Peer Discussion
Frequently asked questions about buprenorphine care; chapter in the Integration of Buprenorphine into HIV Primary Care document.
Curriculum updated on 09/05/2012 -
BESAFE Cultural Competency Model
Guide and promising practices that address cultural competency for specific racial/ethnic populations.Resource updated 09/14/2023
-
Over 50,000 Health Professionals Trained: AETC 2022 Report
In 2021-2022, 56,383 health professionals received training in HIV clinical topics, provided by the HIV clinical training network under HRSA's Ryan White HIV/AIDS Program.News Article updated on 05/06/2024 -
Mpox Treatment Study Underway: How to Take Part
Insights on how to take part in the clinical trial are outlined in HIV.gov's Help Scientists Find a Safe and Effective Mpox Treatment.News Article updated on 05/17/2024 -
HAB Updates its Mpox Info
HRSA's HIV/AIDS Bureau has updated its mpox resources.News Article updated on 05/23/2024 -
HIV Prevention and Care Improvements Summarized in CDC Surveillance Reports
In the U.S., the number of new HIV cases continue to decline, most people are linked to care within one month of their HIV diagnosis, and 69% reach viral suppression within 6 months of HIV diagnosis.News Article updated on 06/10/2024 -
Doxy PEP Guidelines Issued by CDC
CDC has issued the first-ever guidelines recommending use of doxy PEP (doxycycline postexposure prophylaxis) for the prevention of STIs among select populations.News Article updated on 06/06/2024 -
340B Drug Pricing Program
Information on HRSA's Office of Pharmacy Affairs, which administers the 340b program, which provides drug discounts to certain federal grantees,
Resource updated 09/20/2023
-
Clinical Info HIV.gov
U.S. HIV-related treatment guidelines, drug database, and glossary.
Resource updated 09/20/2023
-
Stronger Together
Stronger Together uses counseling to increase engagement in and improve the quality of HIV care available for serodiscordant male couples. Through three in-person and additional “booster” sessions over an 18-month period, Stronger Together gave couples a space to work with an HIV professional to improve treatment adherence and keep both people healthy. Stronger Together participants were more likely to adhere to ART than those in a control group.Resource from the RWHAP Best Practices Compilation updated on 04/12/2024
-
OPT-In For Life
OPT-In For Life is a social media-based intervention that promotes advancement along the HIV care continuum for young adults (ages 18 to 34) with HIV. During the 18-month intervention, OPT-In For Life used multiple social media platforms and a mobile application to provide HIV-related and positive lifestyle resources. Young adults enrolled in OPT-in For Life demonstrated improved retention in HIV care and higher rates of viral suppression after participation.Resource from the RWHAP Best Practices Compilation updated on 03/20/2024
-
Funding Opportunity: RWHAP Part D Women, Infants, Children and Youth Supplemental Funding (HRSA-24-061)
This HRSA HIV/AIDS Bureau pre-application webinar was for the notice of funding opportunity, RWHAP Part D WICY Supplemental Funding (HRSA-24-061).Resource updated 04/09/2024
-
Completing the RWHAP Parts B and B Supplemental Expenditures Reports
Step-by-step instructions for completing the RWHAP Parts B and B Supplemental Expenditures Reports.Resource updated 04/09/2024
-
Opioid Use Among Incarcerated Persons and Impact of Medications
A wealth of data on the impact of substance abuse among incarcerated persons and how medications can make a positive impact are summarized in Quick Take, Medications for Opioid Use Disorder in U.S. Jails and Prisons: Status Update.News Article updated on 04/02/2024 -
Hepatitis Rates Improve Across the Board: CDC Surveillance Report
Rates of hepatitis, across the ABC alphabet, have declined in recent years, according to the 2022 Viral Hepatitis Surveillance Report (CDC, April 2024).News Article updated on 04/09/2024 -
Test & Treat Rapid Access Program
Through the Test & Treat Rapid Access (TTRA) Program, clients with a new HIV diagnosis in Miami-Dade County can access ART, receive other services and counseling, start enrolling in RWHAP, and connect to HIV primary care during the initial visit. At Borinquen Health Care Center, one of the clinical sites participating in TTRA, 76% of clients were virally suppressed within three months of receiving a rapid ART start, and 95% were retained in care for 12 months.Resource from the RWHAP Best Practices Compilation updated on 04/19/2024